Although several CAR T cell therapies for NB have shown promise in preclinical studies (11, 12, 14, 16, 21, 31, 44), only CAR T cells targeting GD2, L1-CAM, or CD276 have reached clinical trials. This evidence concerns the gene CD276 and neuroblastoma.